That's not how it is written here (Another poster cut and pasted this in your previous thread.)
"On October 16, 2013, we entered into an Accelerated Conversion and Note Termination Agreement with JMJ Financial whereby it agreed to exchange all of its outstanding convertible promissory notes (which had an aggregate principal amount of approximately $1,167,000), plus fees of approximately $400,000 for accelerated conversion, note termination and a lock-up, for an aggregate of 783,333 restricted shares of our common stock. JMJ Financial also agreed to certain lock-up restrictions with respect to such shares. Accordingly, JMJ Financial agreed not to sell any of such shares until 60 days after the date of the agreement, following which, until 90 days after the date of the agreement, it agreed to limit the number of such shares it sells on any day to 10% of the trading volume on such day. JMJ Financial also agreed not to engage in any short sales of our common stock at anytime."
How could they sell a block in the morning before they get an idea of how many shares will be traded on that day? If they sell too much in the morning, are over 10% of the day's volume, do they have to buy shares back at the end of the day to stay under 10%?
The stock is going to do about 150,000 shares today (unless a big block is going through right now)...so the most they could have sold today is 15,000 shares, right? 10% of the day's trading volume.
Clearly PRD, cHER2 partnership OR a partnership with Big Pharma based on enhanced efficacy of ADXS-HPV with PD-1 Antibody would be huge no matter which one happened first. If they both happen, WOW!
Latest count I saw was 13.7MM shares of Common Stock PLUS 4.6MM warrants that can convert to additional Common shares at $5.
I'm done buying ... Not because I'm not bullish but only because I'm fully invested and where I want to be here. (Sure, I wish my Break Even were lower.) One thing for sure...I simply could not imagine any reason at all to sell now, especially if you've been holding for any period of time.
Interesting FBG. It's great that this is an independent study (not a study that Advaxis did in the lab in Princeton.) This is from the PR...
"The research was conducted by Dr. Samir N. Khleif and his research team at the Georgia Regents University Cancer Center. Advaxis provided the Lm-LLO immunotherapies and partial research funding. The paper titled “Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy” by Drs. Mkrtichyan, Chong, Eid, Wallecha, Singh, Rothman, and Khleif, has been e-published in the Journal for Immunotherapy of Cancer.
The studies demonstrated that treatment with an Lm-LLO immunotherapy, in combination with an anti-PD-1 antibody, significantly improved immune and therapeutic efficacy in preclinical mouse models. In addition, the study showed that a significant reduction of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC) in both the spleen and the tumor microenvironment were mediated solely by the Lm-LLO immunotherapy. The addition of anti-PD-1 antibody to the Lm-LLO immunotherapy treatment resulted in a significant increase in antigen-specific immune responses in the periphery and in CD8 T cell infiltration into the tumor. As a result, this treatment combination led to significant inhibition of tumor growth and prolonged survival/complete regression of tumors in treated animals.
Given the findings in the mouse model, additional studies were conducted to evaluate activity in human cells. In separate studies, Lm-LLO immunotherapy treatment was found to significantly upregulate surface PD-L1 expression on human monocyte-derived dendritic cells isolated from healthy volunteers. This finding suggests that the combination of Lm-LLO immunotherapy with an anti-PD-1 antibody could have clinical application."
Agree Kwallis. One could argue the terms, but not the results, in other words, I'd have liked to see the Capital Offering at $8 per share and less dilution. That's neither here nor there, at this point.
Best case scenario on CIN is there were indications of efficacy in the readable portions of data (although not statistically valid... sample size too small, and too light in Control patients - so, after all that investment, learnings were no better than Phase 1 learnings.) Also they learned that it wasn't a practical method of treatment vs SOC (and so clearly questioned 'Why do it?) and I believe this is why Rothman departed. Finally, let's not forget they conducted both the low and mid dose cohorts at dosages way lower than what the high dose was set for (CIN high was set as same as India P2 and GOG too) and now call that "old high dose" the "lowest effective dose" ... basically admitting Low and Mid doses weren't effective (or anywhere near high enough.)
My two cents, Easy and FBG...I think anyone who opposed the R/S and the Increased Authorized Share Count...(the Proxy), didn't have faith that 1. The Company could execute the Capital Offering and raise the $20+MM or ever 2. Uplist to Nasdaq CM. (Of course, the multiple iterations/versions of revisions was also aggravating.) If you made the leap of faith with Dan, and looked at what they were asking for and believed they could get 1. & 2. accomplished you voted FOR, if you did not make the leap of faith with Dan and thought they could never practically get 1. & 2. you voted AGAINST. I do think we all realized they were clearly at the end of the road with respect to current financing options and also realized they were in a position of weakness. Where shareholders disagreed (to put it gently) was if the Proxy would be successful at addressing the issues (by accomplishing 1. and 2.) or not. We have to hand it to Dan...he's gotten everything done he said he would.
Not sure Mastiffs. Most likely, if the news were positive they would in fact PR it or at least communicate it publicly. But it's not technically a material event either way, (that was basically my point.)